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Mutations in C12orf62, a Factor that Couples
COX I Synthesis with Cytochrome c Oxidase
Assembly, Cause Fatal Neonatal Lactic Acidosis
Woranontee Weraarpachai,1 Florin Sasarman,1 Tamiko Nishimura,1 Hana Antonicka,1 Karine Aure´,2,3,4
Agne`s Ro¨tig,5 Anne Lombe`s,4,6 and Eric A. Shoubridge1,*
We investigated a family in which the index subject presented with severe congenital lactic acidosis and dysmorphic features associated
with a cytochrome c oxidase (COX)-assembly defect and a specific decrease in the synthesis of COX I, the subunit that nucleates COX
assembly.Using a combinationofmicrocell-mediated chromosome transfer, homozygositymapping, and transcript profiling,wemapped
the gene defect to chromosome 12 and identified a homozygousmissensemutation (c.88G>A) inC12orf62. C12orf62was not detectable
by immunoblot analysis in subject fibroblasts, and retroviral expression of the wild-typeC12orf62 cDNA rescued the biochemical pheno-
type. Furthermore, siRNA-mediated knockdown of C12orf 62 recapitulated the biochemical defect in control cells and exacerbated it in
subject cells.C12orf62 is apparently restricted to the vertebrate lineage. It codes for a very small (6 kDa), uncharacterized, single-transmem-
brane protein that localizes tomitochondria and elutes in a complex of ~110 kDa by gel filtration. COX I, II, and IV coimmunoprecipated
with an epitope-tagged version of C12orf62, and 2D blue-native-polyacrylamide-gel-electrophoresis analysis of newly synthesized
mitochondrial COX subunits in subject fibroblasts showed that COX assembly was impaired and that the nascent enzyme complex
was unstable. We conclude that C12orf62 is required for coordination of the early steps of COX assembly with the synthesis of COX I.Complex IV, or cytochrome c oxidase (COX), is the
terminal enzyme of the respiratory chain and catalyzes
the oxidation of cytochrome c by molecular oxygen. It is
composed of 13 subunits, three of which form the catalytic
core of the enzyme and are encoded in mtDNA. Although
several mutations in the mtDNA-encoded structural sub-
units have been reported,1 most isolated COX deficiencies
(MIM 220110) are inherited as autosomal-recessive disor-
ders and manifest with an early age of onset and a wide
range of clinical phenotypes. These phenotypes include
classical Leigh syndrome, the French-Canadian form of
Leigh syndrome, fatal infantile COX deficiency, cardiomy-
opathy, myopathy, fatal infantile lactic acidosis, and
a reversible COX deficiency in muscles1,2. Mutations in
several nuclear-encoded factors involved in COX biogen-
esis,3–7 as well as in two nuclear-encoded structural sub-
units, have been reported,8,9 but the genetic basis for
many COX deficiencies remains unknown. Independent
of the genetic cause, nearly all COX deficiencies result
from a failure to assemble an adequate amount of func-
tional holoenzyme.
Here, we investigate the genetic basis of a mitochondrial
disorder in a subject who has a COX-assembly defect and
who presented with an unusually severe phenotype. The
index subject (II:1) is the first child of healthy consanguin-
eous Portuguese parents. Two subsequent siblings (II:3,
II:4) later presented with an identical disease, whereas
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gestation. The subject was born at full term; her birth
weight was 3,250 g (50th percentile), and her head circum-
ference was 37 cm (95th percentile). She presented with
neurological and respiratory distress immediately after
birth. She was dysmorphic with hypotelorism, micro-
phthalmia, an ogival palate, and a single palmar crease on
the left hand. Four hours after birth, she had severe meta-
bolic acidosis (pH ¼ 7.03, pCO2 ¼ 30, base excess ¼ 22),
which was associated with ketonuria, thus confirming the
abnormal intermediarymetabolism. Lactate concentration
was 23.4 mM in the blood and 26.2 mM in the cerebro-
spinal fluid 16 hr after birth. Death occurred 24 hr after
birth. An autopsy revealed brain hypertrophy, diffuse alter-
ation of the white-matter myelination, and numerous
cavities in the parieto-occipital region, brainstem, and
cerebellum, as well as hepatomegaly, hypertrophic cardio-
myopathy, renal hypoplasia, and adrenal-gland hyper-
plasia. Her karyotype was normal (46, XX). Informed
consent was obtained from the subject’s parents, and the
research study was approved by the institutional review
board of the Montreal Neurological Institute.
Spectrophotometric assays of whole-cell extracts showed
that COX activity in immortalized subject fibroblasts was
reduced to 30%–40% of that in control fibroblasts.10 Blue
native polyacrylamide gel electrophoresis (BN-PAGE) anal-
ysis11 showed that the reduced activity was associated with
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Figure 1. Defect in COX I Translation and Normal Levels of
Mitochondrial mRNAs in Subject Fibroblasts
(A) Pulse-labeled mitochondrial polypeptides were chased for
10 min (PULSE) or overnight (CHASE). The seven subunits of
complex I (ND), one subunit of complex III (cyt b), three subunits
of complex IV (COX), and two subunits of complex V (ATP) are
indicated at the left of the figure.
(B) Northern blot analysis of fibroblasts from the subject, TACO1
patient, and controls. Ten micrograms of total RNA was separated
on a denaturing formaldehyde agarose gel (MOPS buffer) and
transferred to a nylon membrane. We labeled the PCR products
(300–500 bp) of individual mitochondrial genes (COX I, COX II,
COX III, ND 1, 12S, and 16S) with [a-32P]-dCTP by using the
MegaPrime DNA labeling kit (GE Healthcare). The 12S and 16S
mitochondrial rRNAs and actin were used as loading controls.but did not identify subassemblies of the COX complex
(Figure S1A). Immunoblot analysis showed that the
steady-state levels of COX I and COX II, two mitochondri-
ally encoded COX subunits, and of COX IV, a nuclear-
encoded subunit, had decreased, which is typical for
a defect in COX assembly (Figure S1B). The specific reduc-
tion in the levels of fully assembled COX and COX
subunits prompted us to assess the rate of synthesis and
the stability of the mtDNA-encoded subunits of the
OXPHOS complexes. To this end, mitochondrial transla-
tion products in fibroblasts from the subject and two
controls were pulse labeled with a mixture of [35S] methio-
nine and [35S] cysteine as previously described11 and were
then chased either for 10 min so that the rate of synthesis
of the individual polypeptides could be measured (we refer
to this as the PULSE experiment) or for 17 hr so that their
stability could be assessed (we refer to this as the CHASE
experiment). For the CHASE studies, we incubated cells
for 23 hr in 40 mg/ml chloramphenicol to inhibit mito-
chondrial translation prior to labeling. A specific decrease
in the amount of pulse labeling of the COX I subunit
was observed (approximately 50% compared to that of
the lowest control), whereas the other mtDNA-encoded
polypeptides were apparently synthesized at levels similar
to those in the control cells (Figure 1A). Newly synthesized
COX I appeared much more stable in subject fibroblasts
during the CHASE experiment. To ensure that the decrease
in the synthesis of the COX I polypeptide was not due
to a reduction in the levels of its mRNA, we performed
northern-blot analysis for all mtDNA-encoded COX sub-
units, as well as for a subunit of complex I (ND1) and
both ribosomal RNA subunits (Figure 1B). The levels of
the COX mRNAs in the subject were not reduced relative
to those of the controls when they were normalized to
the rRNA levels, suggesting the presence of a mutation in
a factor specifically involved with COX I translation.
To determine whether the defect was caused by a muta-
tion in nuclear or mitochondrial DNA, we fused patient
and control cells with 143 rho0 cells, which are devoid of
mtDNA. COX activity in the hybrids obtained with subject
fibroblasts was 20% greater than that obtained with
control fibroblasts, demonstrating that the subject’s bio-
chemical defect is most likely an autosomal-recessive trait.
To test whether known COX-assembly factors could sup-
press the defect, we transduced fibroblasts from the subject
with retroviral vectors that express the cDNAs for several
known COX-assembly factors, i.e., COX11, COX16,
COX17, OXA1, SCO2, PET191, SURF1, OXA2, COX10,
COX15.1, COX19, COX15.2, SCO1, and COX23. None of
these factors restored COX activity.
We next attempted to identify the defective gene by mi-
crocell-mediated monochromosomal transfer.3 A panel of
monochromosomal human-mouse hybrid cells contain-
ing single human chromosomes tagged with the chimeric
selection marker HyTK was used as the donor cell line for
human chromosomes.12 All 22 autosomes were transferred
one at a time into subject fibroblasts, and the resultingThe Americclones were tested for complementation of the COX
defect. Rescued clones were considered to be those with
a specific COX activity higher than 60% of control activity,
a percentage that is about double the COX activity in
the subject fibroblasts. Instead of the expected rescue, inan Journal of Human Genetics 90, 142–151, January 13, 2012 143
which a single chromosome carries the wild-type version
of the disease-associated gene, we observed several chro-
mosomes that could apparently restore COX activity
(Table S1). Several of the rescued clones were analyzed
with BN-PAGE, and all displayed control levels of fully
assembled COX (data not shown). One possible explana-
tion for this result was that a mouse chromosome carrying
the murine homolog of the gene mutated in the subject
was transferred along with the individual human chromo-
somes. Fluorescence in situ hybridization (FISH) analysis
confirmed the presence of mouse chromosomes in the
rescued clones (data not shown), and genotyping with
mouse microsatellite markers in the rescued and non-
rescued clones also showed several mouse chromosomal
elements in the tested clones.
We reasoned that identifying the mouse chromosomal
region responsible for the rescue of COX activity could
lead to the identification of the syntenic human chromo-
somal region containing the defective gene. Incorporating
DNA isolated from several rescued and nonrescued clones
with different transferred human chromosomes, Illumina
SNP genotyping (mouse BeadArray technology) identified
parts of mouse chromosomes 1, 11, and 15 exclusively in
rescued clones. However, because the DNA samples con-
tained both mouse and human DNA, the genotype calling
was sometimes ambiguous. Given that the subject is the
child of consanguineous parents, we tried homozygosity
mapping by using an Affymetrix SNP array (GeneChip
250K Nsp I) to identify subject regions of homozygosity
that might be syntenic with the regions identified on the
mouse chromosomes in the rescued clones.
The largest region of LOH (loss of heterozygosity) was on
chromosome 12 at position 43.5–54.2 Mbp. A region span-
ning 90–103.4 Mbp on mouse chromosome 15 is syntenic
with a large region spanning 38.6–55.1 Mbp on human
chromosome 12, and this focused our attention on this
region. Using the HumanWG-6 Expression Bead Chip
(Illumina), we searched this region for transcripts whose
level of expression was low in fibroblast RNA from the
subject compared to11normal anddisease-positive controls
(data not shown). This analysis identified C12orf62 as the
top candidate for the gene that was mutated in the subject.
We used total RNA isolated from subject fibroblasts with
the RNeasy Kit (QIAGEN) to amplify the C12orf62 cDNA
by using the OneStep RT-PCR kit (QIAGEN), and we used
the gel-purified PCR fragments for direct sequencing.
This analysis revealed a homozygous missense mutation
(c.88G>A) (Figure 2A), predicting an amino acid change
from methionine to isoleucine (p.Met19Ile) (Figure 2D).
The mutation was confirmed by restriction fragment-
length polymorphism (RFLP) analysis in subject genomic
DNA after amplification of C12orf62 exon 2. The mutation
abolishes an NlaIII site, and, as predicted, the subject’s PCR
product remained undigested (Figure 2B).
The mutation segregated with the disease phenotype in
the subject’s family (Figure 2C). The two other affected
siblings had the same homozygous mutation, whereas144 The American Journal of Human Genetics 90, 142–151, January 1the unaffected sibling and the parents were heterozygous
carriers of the mutation. C12orf62 contains two exons,
only one of which is coding, and it is predicted to produce
a 57 amino acid protein of about 6 kDa. Orthologs of the
protein appear to be largely confined to the vertebrates,
and the mutated methionine, which is predicted to be in
a transmembrane helix, is conserved in all C12orf62 ortho-
logs. Analysis of more than 80 other patients with COX
deficiency and/or early-onset lactic acidosis failed to iden-
tify additional C12orf62 mutations, suggesting that they
are a rare cause of COX deficiency.
Polyclonal antibodies directed against N- and
C-terminal C12orf62 peptides (MPTGKQLADIGYKT and
CFQWRRAQRQAAEEQKT, respectively) were prepared by
21st Century Biochemicals (Marlboro, MA). Immunoblot
analysis was performed on mitochondrial extracts with
a mixture of these two antibodies, and it showed that
C12orf62 was undetectable in subject fibroblasts but was
present in control cells and also in an individual with
TACO1 mutations (Figures 3A and 3C), suggesting that
the missense mutation destabilizes the protein. To in-
vestigate whether the lack of functional C12orf62 was
responsible for the COX defect, we expressed wild-type
C12orf62 in subject fibroblasts by using a retroviral expres-
sion vector. We amplified the C12orf62 cDNA by using
OneStep RT-PCR (QIAGEN) with specific primers modified
so that they could be cloned into Gateway vectors, and
we cloned the cDNA into a Gateway-compatible pBABE
vector. Retroviral constructs were transiently transfected
into the Phoenix packaging cell line with the HBS/
Ca3(PO4)2method, and fibroblasts were infected 48 hr later
by being exposed to virus-containing medium in the pres-
ence of 4 mg/ml polybrene.13 Expression of C12orf62 in
the controls (Figure 3A) had no measureable effect on the
assembly of the OXPHOS complexes or mitochondrial
translation, but it completely rescued the COX-assembly
defect (Figure 3A), COX I translation in the PULSE assay
(Figure 3B), and COX activity (92% of control) in subject
fibroblasts.
None of the mitochondrial-targeting prediction pro-
grams (Predotar, Target P, MitoPred, MitoProt, or
MitoPWolf) predict C12orf62 to be targeted to mitochon-
dria, although it appears in the MitoCarta database in
multiple tissues, suggesting that C12orf62 is ubiquitously
expressed.14 C12orf62 was also one of the highest-scoring
genes in a screen for OXPHOS gene expression.15 Immuno-
cytochemistry demonstrated the mitochondrial localiza-
tion of C12orf62 in cells expressing a C-terminal, Myc-
tagged version of C12orf62 (Figure S2A); this version was
found to completely rescue the biochemical defect in
subject fibroblasts (data not shown). C12orf62 was present
exclusively in the pellet obtained after alkaline sodium-
carbonate extraction of mitochondria from human embry-
onic kidney (HEK) 293 cells, indicating that C12orf62, like
COX I, is an integral membrane protein, and is not
membrane associated like the 70 kDa subunit of complex II
(Figure S2B).3, 2012
Figure 2. Mutation Analysis of C12orf62 in the Index Subject
(A) Sequence analysis of C12orf62 exon 2 from genomic DNA shows a homozygous c.88G>A missense mutation in the subject fibro-
blasts.
(B) RFLP analysis shows NlaIII of C12orf62 exon 2 amplified from genomic DNA from the subject, TACO1 patient, and three controls
fibroblasts.
(C) Pedigree of the index subject (box) indicates affected and unaffected individuals. The genotype of individuals is shown in paren-
theses as follows: Hom mut, homozygous for c.88G>A; and Het, heterozygous for c.88G>A.
(D) Protein alignment (MultAlin) of C12orf62 in different species. An arrow indicates the conserved methionine mutated in the subject.
The position of the predicted transmembrane domain (predicted with TMHMM Server v. 2.0) is indicated by a gray bar. The color bar
reflects the degree of amino acid conservation between species.To further investigate the function of C12orf62, we used
siRNA-mediated knockdown of the protein. Two Stealth
RNAi duplexes were designed with Block-iT RNAi Express
(Invitrogen). Stealth KD1 (50-AACAGGACUAGAGCGUU
GAUGGUUU-30), stealth KD2 (50-GACAUUGGCUAUAAG
ACCUUCUCUA-30), and the fluorescent oligo control
(Block-iT Alexa FluorRed) were transiently transfected
with Lipofectamine RNAiMAX (Invitrogen) into subjectThe Americand control fibroblasts at a final concentration of 12 nM.
The transfections were repeated on days 3 and 6, and the
cells were harvested and analyzed on day 8. Using both
siRNAs for transient knockdown of C12orf62 in control
fibroblasts resulted in both a COX-assembly defect similar
to that seen in the subject (Figure 4A) and reduced COX
activity (38%–53% of control activity) that correlated
with the severity of the assembly defect. It also resultedan Journal of Human Genetics 90, 142–151, January 13, 2012 145
Figure 3. Rescue of COX Assembly and COX
I Translation Defect in Subject Fibroblasts
(A) BN-PAGE analysis of the assembly of indi-
vidual OXPHOS complexes in control and subject
fibroblasts expressing C12orf62 from a retroviral
vector (upper panel). With complex II subunit
70 kDa as a loading control, SDS-PAGE analysis
of C12orf62 indicates its level of expression
(lower panel).
(B) Pulse labeling with [35S] methionine and [35S]
cysteine of mitochondrial polypeptides and a
10 min chase (PULSE) in control and subject
fibroblasts expressing C12orf62 from a retroviral
vector. The seven subunits of complex I (ND),
one subunit of complex III (cyt b), three subunits
of complex IV (COX), and two subunits of
complex V (ATP) are indicated at the left of the
figure.
(C) SDS-PAGE analysis of C12orf62 steady-state
levels in two controls, TACO1 patient and sub-
ject fibroblasts. Complex II-70kDa subunit and
complexI-39kDa subunit were used as loading
controls.in a decreased intensity of pulse labeling of COX I in the
translation assay (Figure 4B). In the subject fibroblasts,
the same knockdown exacerbated the biochemical pheno-
type, implying that the mutant protein, although not
detectable by immunoblot analysis, retained some residual
function. The knockdown also reduced the stability of
COX I in the subject cells to levels that were indistinguish-
able from those of the controls (Figure 4C). Interestingly,
although siRNA KD2 reduced COX activity to near back-
ground levels, it did not reduce the labeling intensity of
COX I below that seen in KD1 (Figure 4B), implying that
C12orf62 functions in some other aspect of COX biogen-
esis. We conclude that C12orf62 is specifically involved
in the synthesis and subsequent assembly of COX I and
that the presence of a small amount of the mutant protein
in subject cells stabilizes newly synthesized COX I.
To investigate whether C12orf62 interacts or associates
with COX I, we performed a size-exclusion experiment in
HEK 293 cells. The majority of C12orf62 appeared in the
fraction corresponding to a molecular weight (MW) of
about 110 kDa and containing COX I and a small amount
of COX IV (Figure S3), suggesting that C12orf62 interacts
with newly synthesized COX I at an early step in holoen-
zyme assembly. (Fully assembled COX has a MW of about
220 kDa). A minority of C12orf62 also appeared in the
same fraction that contained COX II and COX IV, both
of which are involved in early COX-assembly steps. To
confirm the interaction of C12orf62 and COX 1, we used146 The American Journal of Human Genetics 90, 142–151, January 13, 2012the FLAG antibody to perform immuno-
precipitation of the control fibroblasts
expressing C12orf62-FLAG. Mitochondria
(400 mg) isolated from fibroblasts expressing
C12orf62-FLAG were extracted on ice for
45 min in 100 ml of 50 mM HEPES buffer
(pH7.6), 150 mMNaCl, 1% taurodeoxycho-late, and complete protease inhibitors (Roche). The extract
was centrifuged at 25,000 3 g at 4C for 40 min, and we
precleared the supernatant overnight with noncoated
agarose beads (EZ view Red Protein G Affinity Gel, Sigma)
to reduce nonspecific protein binding. The precleared
extract was used for immunoprecipitation with FLAG-
coated agarose beads (EZ view Red anti-FLAG M2 Affinity
Gel, Sigma). The proteins were eluted from the beads
with 0.1 M glycine (pH 2.5), 0.08% Tween 20, and 1%
DDM. The immunoprecipitated fractions were analyzed
via immunoblotting, and the eluates were precipitated
with trichloroacetic acid and analyzed with mass spec-
trometry (Orbitrap, Thermo Scientific, Waltham, MA)
at the Institute de Recherches Cliniques de Montreal.
C12orf62 coimmunoprecipitated with a small fraction of
COX I, COX II, and COX IV (Figure 5A). Reciprocal immu-
noprecipitation with the COX I and COX II antibodies
verified the interactions (Figure 5B).
To further investigate the function of C12orf62 in the
synthesis of COX I, we searched for binding partners of
C12orf62 by using the FLAG-tagged construct, which we
had previously shown to be functional. C12orf62 coimmu-
noprecipitated with the translation elongation factors
EFTu, LRPPRC, and SLIRP, the latter two of which form
a ribonucleoprotein complex that regulates the stability
and handling of mature mRNAs.15,16 EFTu was not
detected in the control, and LRPPRC and SLIRP were
enriched more than 10-fold (Figure 5C).
Figure 4. Knockdown of C12orf62 in Control and Subject Fibroblasts Results in a Specific Defect in COX Assembly and COX I
Translation
(A) BN-PAGE analysis of the assembly of individual OXPHOS complexes in control and subject fibroblasts transiently transfected with
two different siRNA constructs specific to C12orf62 (KD1 and KD2), with a fluorescent control siRNA (Alexa), and without siRNA (Mock).
Complex IV (OE) is a longer exposure of the same blot.
(B) Pulse labeling with [35S] methionine and [35S] cysteine of mitochondrial polypeptides of the samples in panel (A). The seven subunits
of complex I (ND), one subunit of complex III (cyt b), three subunits of complex IV (COX), and two subunits of complex V (ATP) are
indicated at the left of the figure. For quantification of COX I synthesis, COX I labeling was normalized to the labeling of ND3. COX
activity was also measured in these samples. The values are shown under the translation gel and are expressed as percentages of the
mock control.
(C) The mitochondrial translation products were pulse labeled and chased for 10 min (PULSE) or 17 hr (CHASE) in control and subject
fibroblasts and in cells that were transfected with either a siRNA construct specific to C12orf62 (KD2) or a fluorescent control siRNA
(Alexa). COX I labeling was normalized to the labeling of ND3.The above data suggest that C12orf62 plays a role in the
assembly or stability of the COX complex. To test this, we
pulse labeled the mitochondrial translation products in
the presence of a reversible cytosolic translation inhibitor
(anisomycin) and assessed the stability of thenewly synthe-
sized COX subunits after 8, 17, and 32 hr chases (Figure 6).The AmericThe labeling intensity of the newly synthesized COX
subunits was normalized to ATP6. In control cells, the
labeling intensity of all three COX subunits decreased to
about 20%–30% of that observed in the pulse, even in the
shortest chase (8 hr), indicating that they are apparently
synthesized at levels in excess of that required for newan Journal of Human Genetics 90, 142–151, January 13, 2012 147
Figure 5. C12orf62-FLAG Coimmunoprecipates with COX I, II,
and IV and with LRPPRC, EFTu, and SLIRP
(A) Mitochondria from either fibroblasts expressing C12orf62-
FLAG or control fibroblasts were extracted and incubated with
anti-FLAG agarose beads. Immunoblotting with antibodies against
FLAG, COX I, COX II, and COX IV was performed on each
fraction.
(B) Mitochondria from control fibroblasts expressing C12orf62-
FLAG were extracted and incubated with magnetic beads that
either were uncoated or were coated with COX I or COX II anti-
bodies. Immunoblotting with antibodies against FLAG, COX I,
and COX II was performed on the input, unbound, and eluate
fractions.
(C) The immunoprecipitation was performed with FLAG beads
as described in (A), and immunoblotting with antibodies
against FLAG, LRPPRC, EFTu, and SLIRP was performed on each
fraction.
148 The American Journal of Human Genetics 90, 142–151, January 1assemblyof theCOXholoenzyme (Figure6B). In the subject
cells, although COX I was synthesized at ~25% of control
levels, thenewly synthesizedproteinwas completely stable.
This contrasted with COX II and COX III, whose turnover
was much faster than in control cells (Figure 6B).
Incorporation of the newly synthesized mtDNA-
encoded COX subunits into the holoenzyme complex
was assessed with 2D BN-PAGE (Figure 7). For this analysis,
30 mg of 35S-labeled mitochondrial translation products
was run in the first dimension on 8%–12% nondenaturing
polyacrylamide gradient gels, followed by a separation on
10%–16% Tricine-SDS gradient gels.17 In control cells,
COX I is incorporated into two complexes, one corre-
sponding to the fully assembled holoenzyme (S4) and
another lower-molecular-weight complex corresponding
to an intermediate assembly complex (S3).18 A similar
pattern was observed in the subject cells: COX I stability
appeared normal in the fully assembled complex but
slightly decreased in the assembly intermediate. By con-
trast, newly synthesized COX II and III were less efficiently
incorporated into the COX complex, and they were rapidly
turned over after a long chase.
Together, the results of this study suggest that the role
of C12orf62 is to couple the synthesis of COX I with sub-
sequent assembly of the nascent subunits into the holoen-
zyme complex. This function is reminiscent of S. cerevisiae
Mss51p, a protein that acts both as a translator activator for
COX1mRNA and as an early assembly factor in a heteroli-
gomeric complex. Mss51p binds to the 50 UTR of the COX1
mRNA to control translation and also associates with
several other proteins in a high-molecular-weight complex
to assist in early assembly; such proteins include Cox14p,
Surf1p, Coa1p, and Coa3p.19 The current model proposes
that Mss51p exists in two pools, one that can activate
COX1 translation and another that assists in chaperoning
Cox1p in the assembly process. This, then, would serve to
couple the supply of newly synthesized Cox1p subunits
with demand.
It is still not clear exactly how translation initiation of
the mitochondrial mRNAs occurs in mammals because
most mammalian mitochondrial mRNAs lack significant
50 UTRs; however, the existence of a family of translational
activator proteins analogous to those in yeast seems prob-
able. Only one such protein, TACO1, has been identified to
date in mammals. It is essential for the efficient translation
of full-length COX I, but the molecular mechanism re-
mains unknown.7 Deletion mutants of the yeast ortholog
of TACO1 (YGR021w) have normal Cox1p synthesis and
respire normally, indicating that the protein has evolved
a different function in mammals. C12orf62 is essential
for the normal level of COX I labeling in a pulse-transla-
tion experiment, and the labeling intensity of newly syn-
thesized COX I correlates with the severity of the COX-
assembly defect up to a point. Although we cannot be
certain that this represents a true synthesis defect rather
than rapid proteolysis of the newly synthesized COX I
polypeptide, a number of observations argue against the3, 2012
Figure 6. Synthesis and Turnover of COX Subunits in Control and Subject Fibroblasts
(A) Pulse labeling with [35S] methionine and [35S] cysteine of mitochondrial polypeptides and a 10min chase (PULSE), as well as the time
course of degradation via chases for 8, 17, and 32 hr (CHASE) are shown in control and subject fibroblasts. The seven subunits of complex
I (ND), one subunit of complex III (cyt b), three subunits of complex IV (COX), and two subunits of complex V (ATP) are indicated at the
left of the figure.
(B) Histograms in which the level of the three COX subunits is normalized to the level of ATP6 in the PULSE and CHASE experiments
in (A).latter. First, in fibroblasts that are null for TACO1, prema-
turely truncated forms of COX I accumulate in the pulse
and are only turned over in a longer chase,7 suggesting
that the quality-control system does not immediately
recognize unassembled COX I subunits. Second, both
LRPPRC and SLIRP, which form a ribonucleoprotein
complex with COX I mRNA and are essential for its
stability,16 are enriched more than 10-fold in the immuno-
precipitate of C12orf62, suggesting that C12orf62 plays
a direct role in the synthesis of COX I. Finally, although
newly synthesized COX I turns over rapidly in the context
of other reported COX-assembly defects such as those
related to SCO111 or TACO1,7 it is completely stable in
the subject fibroblasts.
The immunoprecipitation data suggest that the majority
of C12orf62 interacts with the newly synthesized core
subunits of COX. It also coelutes on a size-exclusion
columnwith a fraction of COX I and COX IV, two subunits
that nucleate the earliest step of COX assembly.18 Many
small single-transmembrane proteins are structural com-
ponents of the OXPHOS complexes, and it has beenThe Americproposed that they might function to organize the hydro-
phobic domains of these complexes.20 One possibility is
that C12orf62 acts to stabilize COX I in the inner mem-
brane, allows COX I to assemble with COX IV and COX
Va, and permits the addition of heme A and the two copper
atoms that are necessary to mature this subunit. This
activity might make C12orf62 unavailable for a role in
translation.
The translation factor EFTu also coimmunoprecipitated
with C12orf62-FLAG. Although its major role is delivering
aminoacyl-tRNAs to the acceptor (A) site on the ribosome
during the elongation stage of translation, it also appears
to have a chaperone function.21 It interacts with mis-
folded, newly synthesized polypeptides from the mito-
chondrial ribosome, prevents thermal aggregation of
proteins in vitro, and enhances protein refolding in vitro.
Thus, EFTu could have a role in quality control of the
nascent COX enzyme complexes through the binding of
C12orf62.
Surprisingly, despite the fact that COX activity in the
patient fibroblasts was 30%–40% of that in the controlan Journal of Human Genetics 90, 142–151, January 13, 2012 149
Figure 7. COX Subunits II and III Are Not Prop-
erly Assembled into the Nascent COX Complex
in Subject Fibroblasts
2D BN-PAGE analysis of the sample pulse that
was labeled with [35S] methionine and [35S]
cysteine and chased for 32 hr. The gels were dried
and the labeled mitochondrial translation prod-
ucts were detected through direct autoradiog-
raphy. The arrows show different mtDNA-
encoded polypeptides: one complex III subunit
(cyt b), two complex V subunits (ATP6 and
ATP8), COX subunit 1 (COX I-S4) in fully assem-
bled complex IV, COX subunit 1 (COX I-S3) in
the S3 intermediate of complex IV, COX subunit 2
(COX II), and COX subunit 3 (COX III) in fully
assembled COX. The amount of label in each of
the identified COX subunits was normalized to
the label in ATP6 and is shown beneath the figure
for both the 17 and 32 hr chases.fibroblasts, the phenotypic presentation and clinical
outcome in the subject investigated here are much more
severe than that of SURF1 3- or TACO1-7 mutation-positive
patients, whose fibroblasts have even less fully assembled
COX. This most likely reflects tissue-specific requirements
for the individual COX-assembly factors;22,23 however,
because all of these factors are ubiquitously expressed,
the molecular basis for this specificity remains unclear.
A resolution of this question awaits the development of
appropriate cellular or animal models of disease.Supplemental Data
Supplemental Data include three figures, one table, and supple-
mental references and can be found with this article online at
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